Login to Your Account

Clinic Roundup

Tuesday, September 4, 2012

• Sophiris Bio Inc., of La Jolla, Calif., reported data from a Phase I/II safety study, in which PRX302 was well tolerated through three months following a transrectal injection.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription